News Release | SEIKAGAKU CORPORATION

05.13.2025 [Summary]Consolidated Financial Results (Japan GAAP) (Summary) for the Fiscal 2024 (Year Ended March 31, 2025) （494KB）

読む [Summary]Consolidated Financial Results (Japan GAAP) (Summary) for the Fiscal 2024 (Year Ended March 31, 2025)

04.25.2025 Seikagaku and Ono Reach a Basic Agreement Related to Co-development and Marketing Collaboration on Gel-One in Japan （3,945KB）

読む Seikagaku and Ono Reach a Basic Agreement Related to Co-development and Marketing Collaboration on Gel-One in Japan

03.26.2025 Seikagaku Announces Revision of Forecast of Full-Year Consolidated Financial Results for the Fiscal Year Ending March 31, 2025 （3,853KB）

読む Seikagaku Announces Revision of Forecast of Full-Year Consolidated Financial Results for the Fiscal Year Ending March 31, 2025

03.12.2025 Seikagaku Announces Receipt of a Complete Response Letter Concerning the Biologics License Application in the U.S. for SI-6603 (Generic Name: Condoliase) （133KB）

読む Seikagaku Announces Receipt of a Complete Response Letter Concerning the Biologics License Application in the U.S. for SI-6603 (Generic Name: Condoliase)

02.21.2025 Seikagaku Announces Initiation of Phase III Clinical Studies of Gel-One, a Treatment of Osteoarthritis, in Japan （3,943KB）

読む Seikagaku Announces Initiation of Phase III Clinical Studies of Gel-One, a Treatment of Osteoarthritis, in Japan

02.07.2025 Consolidated Financial Results for the Third Quarter of Fiscal year 2024 （218KB）

読む Consolidated Financial Results for the Third Quarter of Fiscal year 2024

11.08.2024 Consolidated Financial Results for the Second Quarter of Fiscal Year 2024 （309KB）

読む Consolidated Financial Results for the Second Quarter of Fiscal Year 2024

10.16.2024 Seikagaku Announces Regulatory Approval in China for MucoUp, a Submucosal Injection Agent for Endoscopic Surgery, and Conclusion of a Distribution Agreement with Tozai Boeki Kaisha, Ltd. （140KB）

読む Seikagaku Announces Regulatory Approval in China for MucoUp, a Submucosal Injection Agent for Endoscopic Surgery, and Conclusion of a Distribution Agreement with Tozai Boeki Kaisha, Ltd.

08.05.2024 Consolidated Financial Results for the First Quarter of Fiscal 2024 （292KB）

読む Consolidated Financial Results for the First Quarter of Fiscal 2024

05.23.2024 Convocation Notice of the 78th Ordinary General Meeting of Shareholders （174KB）

読む Convocation Notice of the 78th Ordinary General Meeting of Shareholders

05.14.2024 Seikagaku Announces the Biologics License Application for SI-6603 Has Been Accepted for Filing by the U.S. FDA （141KB）

読む Seikagaku Announces the Biologics License Application for SI-6603 Has Been Accepted for Filing by the U.S. FDA

05.13.2024 Consolidated Financial Results for the Fiscal Year Ended March 31, 2024 （384KB）

読む Consolidated Financial Results for the Fiscal Year Ended March 31, 2024

05.13.2024 Seikagaku Announces Differences between Full-Year Consolidated Financial Forecasts （226KB）

読む Seikagaku Announces Differences between Full-Year Consolidated Financial Forecasts

04.09.2024 Seikagaku Announces an Academic Conference Presentation on SI-6603 by Licensee Ferring Pharmaceuticals Inc. （240KB）

読む Seikagaku Announces an Academic Conference Presentation on SI-6603 by Licensee Ferring Pharmaceuticals Inc.

02.14.2024 Consolidated Financial Results for the Third Quarter of Fiscal year 2023 （222KB）

読む Consolidated Financial Results for the Third Quarter of Fiscal year 2023

11.08.2023 Consolidated Financial Results for the Second Quarter of Fiscal Year 2023 （259KB）

読む Consolidated Financial Results for the Second Quarter of Fiscal Year 2023

08.04.2023 Consolidated Financial Results for the First Quarter of Fiscal 2023 （227KB）

読む Consolidated Financial Results for the First Quarter of Fiscal 2023

07.21.2023 Seikagaku Announces Favorable Results from a Pivotal Study for SI-449, an Adhesion Barrier （141KB）

読む Seikagaku Announces Favorable Results from a Pivotal Study for SI-449, an Adhesion Barrier

05.26.2023 Seikagaku Announces the Topline Results from a Phase III Clinical Study (Additional Study) in the U.S. for SI-6603, a Treatment for Lumbar Disc Herniation （72KB）

読む Seikagaku Announces the Topline Results from a Phase III Clinical Study (Additional Study) in the U.S. for SI-6603, a Treatment for Lumbar Disc Herniation

05.22.2023 Convocation Notice of the 77th Ordinary General Meeting of Shareholders （302KB）

読む Convocation Notice of the 77th Ordinary General Meeting of Shareholders

05.12.2023 Consolidated Financial Results for the Fiscal Year Ended March 31, 2023 （168KB）

読む Consolidated Financial Results for the Fiscal Year Ended March 31, 2023

02.08.2023 Consolidated Financial Results for the Thrid Quarter of Fiscal year 2022 （103KB）

読む Consolidated Financial Results for the Thrid Quarter of Fiscal year 2022

12.26.2022 Seikagaku announces Results of Acquisition of Treasury Stocks and its Completion （73KB）

読む Seikagaku announces Results of Acquisition of Treasury Stocks and its Completion

12.01.2022 Seikagaku announces the Progress of Acquisition of Treasury Stocks （72KB）

読む Seikagaku announces the Progress of Acquisition of Treasury Stocks

11.17.2022 Seikagaku Announces a New Mid-term Management Plan (Fiscal 2022 to Fiscal 2025) （97KB）

読む Seikagaku Announces a New Mid-term Management Plan (Fiscal 2022 to Fiscal 2025)

11.08.2022 Seikagaku Announces Dividend from Retained Earnings (Interim Dividend) and Revision to Year-End Dividend Forecast （66KB）

読む Seikagaku Announces Dividend from Retained Earnings (Interim Dividend) and Revision to Year-End Dividend Forecast

11.08.2022 Consolidated Financial Results for the Second Quarter of Fiscal Year 2022 （111KB）

読む Consolidated Financial Results for the Second Quarter of Fiscal Year 2022

11.01.2022 Seikagaku announces the Progress of Acquisition of Treasury Stocks （72KB）

読む Seikagaku announces the Progress of Acquisition of Treasury Stocks

10.03.2022 Seikagaku announces the Progress of Acquisition of Treasury Stocks （72KB）

読む Seikagaku announces the Progress of Acquisition of Treasury Stocks

09.01.2022 Seikagaku announces the Progress of Acquisition of Treasury Stocks （72KB）

読む Seikagaku announces the Progress of Acquisition of Treasury Stocks

08.05.2022 Consolidated Financial Results for the First Quarter of Fiscal 2022 （109KB）

読む Consolidated Financial Results for the First Quarter of Fiscal 2022

08.01.2022 Seikagaku announces the Progress of Acquisition of Treasury Stocks （72KB）

読む Seikagaku announces the Progress of Acquisition of Treasury Stocks

07.01.2022 Seikagaku announces the Progress of Acquisition of Treasury Stocks （72KB）

読む Seikagaku announces the Progress of Acquisition of Treasury Stocks

06.01.2022 Seikagaku announces the Progress of Acquisition of Treasury Stocks （71KB）

読む Seikagaku announces the Progress of Acquisition of Treasury Stocks

05.23.2022 Convocation Notice of the 76th Ordinary General Meeting of Shareholders （206KB）

読む Convocation Notice of the 76th Ordinary General Meeting of Shareholders

05.13.2022 Seikagaku announces Acquisition of Treasury Stocks （65KB）

読む Seikagaku announces Acquisition of Treasury Stocks

05.13.2022 Consolidated Financial Results for the Fiscal Year Ended March 31, 2022 （191KB）

読む Consolidated Financial Results for the Fiscal Year Ended March 31, 2022

05.13.2022 Seikagaku Initiates a Phase III Clinical Study for SI-614, a Therapeutic Agent for Dry Eye, in the U.S. （69KB）

読む Seikagaku Initiates a Phase III Clinical Study for SI-614, a Therapeutic Agent for Dry Eye, in the U.S.

02.08.2022 Consolidated Financial Results for the Third Quarter of Fiscal year 2021 （128KB）

読む Consolidated Financial Results for the Third Quarter of Fiscal year 2021

01.26.2022 Seikagaku Announces the Establishment of a New Company in Canada （35KB）

読む Seikagaku Announces the Establishment of a New Company in Canada

11.16.2021 Seikagaku Announces PyroSmart NextGen recombinant BET reagent receives the Pharma Manufacturing 2021 Innovation Award （100KB）

読む Seikagaku Announces PyroSmart NextGen recombinant BET reagent receives the Pharma Manufacturing 2021 Innovation Award

11.10.2021 Seikagaku Announces Release of One Millionth Horseshoe Crab from Species Sustainability Project by Associates of Cape Cod, Inc. （164KB）

読む Seikagaku Announces Release of One Millionth Horseshoe Crab from Species Sustainability Project by Associates of Cape Cod, Inc.

11.09.2021 Seikagaku Announces Application for Selection of New Market Segment "Prime Market" on the Tokyo Stock Exchange （68KB）

読む Seikagaku Announces Application for Selection of New Market Segment "Prime Market" on the Tokyo Stock Exchange

11.09.2021 Consolidated Financial Results for the Second Quarter of Fiscal Year 2021 （111KB）

読む Consolidated Financial Results for the Second Quarter of Fiscal Year 2021

08.02.2021 Seikagaku Announces the Launch of HyLink, an Intra-Articular Single-Injection Viscosupplement for the Treatment of Knee Osteoarthritis in Taiwan （122KB）

読む Seikagaku Announces the Launch of HyLink, an Intra-Articular Single-Injection Viscosupplement for the Treatment of Knee Osteoarthritis in Taiwan

07.30.2021 Consolidated Financial Results for the First Quarter of Fiscal 2021 （131KB）

読む Consolidated Financial Results for the First Quarter of Fiscal 2021

07.19.2021 Seikagaku announces Results of Acquisition of Treasury Stocks and its Completion （209KB）

読む Seikagaku announces Results of Acquisition of Treasury Stocks and its Completion

05.24.2021 Convocation Notice of the 75th Ordinary General Meeting of Shareholders （117KB）

読む Convocation Notice of the 75th Ordinary General Meeting of Shareholders

05.19.2021 Ono and Seikagaku Announce the Launch of JOYCLU 30mg Intra-articular Injection, a Joint Function Improvement Agent, in Japan （103KB）

読む Ono and Seikagaku Announce the Launch of JOYCLU 30mg Intra-articular Injection, a Joint Function Improvement Agent, in Japan

05.13.2021 Seikagaku announces Acquisition of Treasury Stocks （26KB）

読む Seikagaku announces Acquisition of Treasury Stocks

05.13.2021 Seikagaku Announces Dividend from Retained Earnings (Commemorative Dividend) for the Fiscal Year Ended March 31, 2021 and Forecast of Dividend from Retained Earnings (Special Dividend) for the Fiscal Year Ending March 31, 2022 （164KB）

読む Seikagaku Announces Dividend from Retained Earnings (Commemorative Dividend) for the Fiscal Year Ended March 31, 2021 and Forecast of Dividend from Retained Earnings (Special Dividend) for the Fiscal Year Ending March 31, 2022

05.13.2021 Consolidated Financial Results for the Fiscal Year Ended March 31, 2021 （181KB）

読む Consolidated Financial Results for the Fiscal Year Ended March 31, 2021

04.27.2021 Seikagaku Announces Revision of Forecast of Full-Year Consolidated Financial Results for the Fiscal Year Ending March 31, 2021 （81KB）

読む Seikagaku Announces Revision of Forecast of Full-Year Consolidated Financial Results for the Fiscal Year Ending March 31, 2021

04.26.2021 Seikagaku Announces Launch of PyroSmart NextGen Recombinant LAL Reagent by Associates of Cape Cod, Inc. （358KB）

読む Seikagaku Announces Launch of PyroSmart NextGen Recombinant LAL Reagent by Associates of Cape Cod, Inc.

03.23.2021 Ono and Seikagaku Announce a Manufacturing and Marketing Approval in Japan for JOYCLU 30mg Intra-articular Injection, a Joint Function Improvement Agent, for the Indication of Osteoarthritis (Knee Joint and Hip Joint) （114KB）

読む Ono and Seikagaku Announce a Manufacturing and Marketing Approval in Japan for JOYCLU 30mg Intra-articular Injection, a Joint Function Improvement Agent, for the Indication of Osteoarthritis (Knee Joint and Hip Joint)

02.05.2021 Consolidated Financial Results for the Thrid Quarter of Fiscal year 2020 （133KB）

読む Consolidated Financial Results for the Thrid Quarter of Fiscal year 2020

02.05.2021 Seikagaku Announces Forecast of Consolidated Financial Results and Dividend Forecast （86KB）

読む Seikagaku Announces Forecast of Consolidated Financial Results and Dividend Forecast

11.11.2020 Consolidated Financial Results for the Second Quarter of Fiscal Year 2020

読む Consolidated Financial Results for the Second Quarter of Fiscal Year 2020

09.30.2020 Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea （363KB）

読む Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea

09.24.2020 Seikagaku Announces Forecast of Consolidated Financial Results and Dividend Forecast （87KB）

読む Seikagaku Announces Forecast of Consolidated Financial Results and Dividend Forecast

08.27.2020 Announcement Concerning a COVID-19 Vaccine Development Partnership with VIDO-InterVac at Dalton Chemical Laboratories, Inc. （127KB）

読む Announcement Concerning a COVID-19 Vaccine Development Partnership with VIDO-InterVac at Dalton Chemical Laboratories, Inc.

07.31.2020 Consolidated Financial Results for the First Quarter of Fiscal 2020 （107KB）

読む Consolidated Financial Results for the First Quarter of Fiscal 2020

06.26.2020 (Update of Previous Disclosure) Seikagaku Announces Completion of Acquisition (Incorporation as a Subsidiary) of Dalton Chemical Laboratories, Inc. and Change in Specified Subsidiaries （169KB）

読む (Update of Previous Disclosure) Seikagaku Announces Completion of Acquisition (Incorporation as a Subsidiary) of Dalton Chemical Laboratories, Inc. and Change in Specified Subsidiaries

06.11.2020 Ono and Seikagaku Announce the Results from a Phase III Clinical Study in Japan of ONO-5704/SI-613 in Patients with Knee Osteoarthritis Presented at an Academic Conference （174KB）

読む Ono and Seikagaku Announce the Results from a Phase III Clinical Study in Japan of ONO-5704/SI-613 in Patients with Knee Osteoarthritis Presented at an Academic Conference

06.04.2020 Convocation Notice of the 74th Ordinary General Meeting of Shareholders （144KB）

読む Convocation Notice of the 74th Ordinary General Meeting of Shareholders

05.21.2020 Seikagaku Initiates a Pivotal Study for SI-449, an Adhesion Barrier （129KB）

読む Seikagaku Initiates a Pivotal Study for SI-449, an Adhesion Barrier

05.19.2020 Consolidated Financial Results for Fiscal 2019 (Year Ended March 31, 2020)

読む Consolidated Financial Results for Fiscal 2019 (Year Ended March 31, 2020)

05.19.2020 Seikagaku Announces Difference between Consolidated Financial Forecasts and Actual Results （48KB）

読む Seikagaku Announces Difference between Consolidated Financial Forecasts and Actual Results

05.19.2020 Seikagaku announces the Discontinuation (revocation) of Policy Against Large-scale Purchases of the Company’s Shares (Takeover Defense Measures) （71KB）

読む Seikagaku announces the Discontinuation (revocation) of Policy Against Large-scale Purchases of the Company’s Shares (Takeover Defense Measures)

04.01.2020 Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China （291KB）

読む Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China

02.28.2020 Seikagaku Announces Acquisition (Incorporation as a subsidiary) of Dalton Chemical Laboratories, Inc. of Canada （84KB）

読む Seikagaku Announces Acquisition (Incorporation as a subsidiary) of Dalton Chemical Laboratories, Inc. of Canada

02.04.2020 Consolidated Financial Results for the Thrid Quarter of Fiscal year 2019

読む Consolidated Financial Results for the Thrid Quarter of Fiscal year 2019

01.06.2020 Ono and Seikagaku Submit a New Drug Application for Manufacturing and Marketing Approval for ONO-5704/SI-613 for the Treatment of Osteoarthritis in Japan （98KB）

読む Ono and Seikagaku Submit a New Drug Application for Manufacturing and Marketing Approval for ONO-5704/SI-613 for the Treatment of Osteoarthritis in Japan

11.08.2019 Consolidated Financial Results for the Second Quarter of Fiscal Year 2019

読む Consolidated Financial Results for the Second Quarter of Fiscal Year 2019

11.08.2019 Seikagaku Announces a New Mid-term Management Plan (Fiscal 2019 to Fiscal 2021) （114KB）

読む Seikagaku Announces a New Mid-term Management Plan (Fiscal 2019 to Fiscal 2021)

11.08.2019 Seikagaku Announces the Recognition of an Extraordinary Loss (Impairment Loss) （41KB）

読む Seikagaku Announces the Recognition of an Extraordinary Loss (Impairment Loss)

11.08.2019 Seikagaku Initiates a Phase I/II Clinical Study for SI-722 in the U.S., an Indication for Interstitial Cystitis and Bladder Pain Syndrome （22KB）

読む Seikagaku Initiates a Phase I/II Clinical Study for SI-722 in the U.S., an Indication for Interstitial Cystitis and Bladder Pain Syndrome

07.31.2019 Consolidated Financial Results for the First Quarter of Fiscal 2019 （81KB）

読む Consolidated Financial Results for the First Quarter of Fiscal 2019

05.28.2019 Convocation Notice of the 73rd Ordinary General Meeting of Shareholders （248KB）

読む Convocation Notice of the 73rd Ordinary General Meeting of Shareholders

05.10.2019 Consolidated Financial Results for Fiscal 2018 (Year Ended March 31, 2019)

読む Consolidated Financial Results for Fiscal 2018 (Year Ended March 31, 2019)

04.23.2019 Seikagaku Announces Revision of Consolidated Financial Forecasts for the Fiscal 2018 ending March 2019 （117KB）

読む Seikagaku Announces Revision of Consolidated Financial Forecasts for the Fiscal 2018 ending March 2019

03.22.2019 Seikagaku Launches HyLink, an Intra-Articular Single-Injection Viscosupplement for the Treatment of Knee Osteoarthritis in Italy （79KB）

読む Seikagaku Launches HyLink, an Intra-Articular Single-Injection Viscosupplement for the Treatment of Knee Osteoarthritis in Italy

02.19.2019 Ono and Seikagaku Announce the Topline Results from Phase III Confirmatory Study of ONO-5704/SI-613 in Patients with Knee Osteoarthritis in Japan （63KB）

読む Ono and Seikagaku Announce the Topline Results from Phase III Confirmatory Study of ONO-5704/SI-613 in Patients with Knee Osteoarthritis in Japan

02.05.2019 Consolidated Financial Results for the Thrid Quarter of Fiscal year 2018

読む Consolidated Financial Results for the Thrid Quarter of Fiscal year 2018

11.07.2018 Consolidated Financial Results for the Second Quarter of Fiscal Year 2018

読む Consolidated Financial Results for the Second Quarter of Fiscal Year 2018

07.31.2018 Seikagaku and Kaken Announce the Launch of HERNICORE 1.25 Units for Intradiscal Injection in Japan, Indicated for Treatment of Lumbar Disc Herniation （390KB）

読む Seikagaku and Kaken Announce the Launch of HERNICORE 1.25 Units for Intradiscal Injection in Japan, Indicated for Treatment of Lumbar Disc Herniation

07.31.2018 Consolidated Financial Results for the First Quarter of Fiscal 2018

読む Consolidated Financial Results for the First Quarter of Fiscal 2018

07.05.2018 Seikagaku announces Results of Acquisition of Treasury Stocks and its Completion （31KB）

読む Seikagaku announces Results of Acquisition of Treasury Stocks and its Completion

07.02.2018 Seikagaku announces the Progress of Acquisition of Treasury Stocks （31KB）

読む Seikagaku announces the Progress of Acquisition of Treasury Stocks

06.14.2018 Seikagaku announces Acquisition of Treasury Stocks （17KB）

読む Seikagaku announces Acquisition of Treasury Stocks

05.29.2018 Convocation Notice of the 72nd Ordinary General Meeting of Shareholders

読む Convocation Notice of the 72nd Ordinary General Meeting of Shareholders

05.22.2018 Seikagaku and Kaken Announce the Listing in the National Health Insurance Drug Price List and Launch Date of HERNICORE 1.25 Units for Intradiscal Injection in Japan, Indicated for Treatment of Lumbar Disc Herniation （42KB）

読む Seikagaku and Kaken Announce the Listing in the National Health Insurance Drug Price List and Launch Date of HERNICORE 1.25 Units for Intradiscal Injection in Japan, Indicated for Treatment of Lumbar Disc Herniation

05.21.2018 Seikagaku Initiates a Clinical Trial for SI-449, an Adhesion Barrier （18KB）

読む Seikagaku Initiates a Clinical Trial for SI-449, an Adhesion Barrier

05.11.2018 Consolidated Financial Results for Fiscal 2017 (Year Ended March 31, 2018)

読む Consolidated Financial Results for Fiscal 2017 (Year Ended March 31, 2018)

03.30.2018 Seikagaku Announces Revision of Consolidated Financial Forecasts for the Fiscal 2017 ending March 2018 （64KB）

読む Seikagaku Announces Revision of Consolidated Financial Forecasts for the Fiscal 2017 ending March 2018

03.23.2018 Seikagaku Announces New Drug Application Approval of HERNICORE 1.25 Units for Intradiscal Injection in Japan, Indicated for Treatment of Lumbar Disc Herniation. （27KB）

読む Seikagaku Announces New Drug Application Approval of HERNICORE 1.25 Units for Intradiscal Injection in Japan, Indicated for Treatment of Lumbar Disc Herniation.

02.19.2018 Seikagaku Initiates a Phase III Clinical Trial (Additional Study) in the U.S. for SI-6603, Indicated for Treatment of Lumbar Disc Herniation （42KB）

読む Seikagaku Initiates a Phase III Clinical Trial (Additional Study) in the U.S. for SI-6603, Indicated for Treatment of Lumbar Disc Herniation

02.02.2018 Consolidated Financial Results for the Thrid Quarter of Fiscal year 2017

読む Consolidated Financial Results for the Thrid Quarter of Fiscal year 2017

11.07.2017 Consolidated Financial Results for the Second Quarter of Fiscal Year 2017

読む Consolidated Financial Results for the Second Quarter of Fiscal Year 2017

11.07.2017 Seikagaku Announces the Results of SI-6603 Phase III Clinical Trials in the U.S., Indicated for Treatment of Lumbar Disc Herniation （43KB）

読む Seikagaku Announces the Results of SI-6603 Phase III Clinical Trials in the U.S., Indicated for Treatment of Lumbar Disc Herniation

09.28.2017 Ono and Seikagaku Announce Initiation of a Late-Stage Phase II Clinical Trial of SI-613 for Treatment of Enthesopathy （58KB）

読む Ono and Seikagaku Announce Initiation of a Late-Stage Phase II Clinical Trial of SI-613 for Treatment of Enthesopathy

09.01.2017 Ono and Seikagaku Reach a Definitive Agreement Related to Co-development and Marketing Collaboration on SI-613 for the Treatment of Osteoarthritis in Japan （31KB）

読む Ono and Seikagaku Reach a Definitive Agreement Related to Co-development and Marketing Collaboration on SI-613 for the Treatment of Osteoarthritis in Japan

07.31.2017 Consolidated Financial Results for the First Quarter of Fiscal 2017

読む Consolidated Financial Results for the First Quarter of Fiscal 2017

06.16.2017 Seikagaku Initiates Phase II Study of SI-613 for Treatment of Knee Osteoarthritis in the U.S. （44KB）

読む Seikagaku Initiates Phase II Study of SI-613 for Treatment of Knee Osteoarthritis in the U.S.

05.12.2017 Consolidated Financial Results for Fiscal 2016 (Year Ended March 31, 2017)

読む Consolidated Financial Results for Fiscal 2016 (Year Ended March 31, 2017)

05.12.2017 Seikagaku and Ono Reach a Basic Agreement Related to Co-development and Marketing Collaboration on SI-613 for the Treatment of Osteoarthritis in Japan （32KB）

読む Seikagaku and Ono Reach a Basic Agreement Related to Co-development and Marketing Collaboration on SI-613 for the Treatment of Osteoarthritis in Japan

05.12.2017 Seikagaku Announces Dividend from Retained Earnings (70th Anniversary Commemorative Dividend) （44KB）

読む Seikagaku Announces Dividend from Retained Earnings (70th Anniversary Commemorative Dividend)

02.03.2017 Consolidated Financial Results for the Thrid Quarter of Fiscal 2016

読む Consolidated Financial Results for the Thrid Quarter of Fiscal 2016

02.03.2017 Seikagaku Initiates Phase III Study of SI-613 for Treatment of Osteoarthritis in Japan （46KB）

読む Seikagaku Initiates Phase III Study of SI-613 for Treatment of Osteoarthritis in Japan

11.08.2016 Consolidated Financial Results for the Second Quarter of Fiscal Year 2016

読む Consolidated Financial Results for the Second Quarter of Fiscal Year 2016

11.08.2016 Seikagaku Announces Exclusive Distributorship Agreement in the U.S. for VISCO-3, A Three-Injection Viscosupplement Product （44KB）

読む Seikagaku Announces Exclusive Distributorship Agreement in the U.S. for VISCO-3, A Three-Injection Viscosupplement Product

08.29.2016 Seikagaku Announces the Conclusion of an Exclusive Worldwide License Agreement (excluding Japan) for SI-6603, a Novel Treatment for Lumbar Disc Herniation （45KB）

読む Seikagaku Announces the Conclusion of an Exclusive Worldwide License Agreement (excluding Japan) for SI-6603, a Novel Treatment for Lumbar Disc Herniation

08.01.2016 Seikagaku announces Results of Acquisition of Treasury Stocks and its Completion （38KB）

読む Seikagaku announces Results of Acquisition of Treasury Stocks and its Completion

07.28.2016 Consolidated Financial Results for the First Quarter of Fiscal 2016

読む Consolidated Financial Results for the First Quarter of Fiscal 2016

06.15.2016 Seikagaku announces the conclusion of a Letter of Intent for an Overseas Exclusive License Agreement for SI-6603, a Novel Treatment for Lumbar Disc Herniation （19KB）

読む Seikagaku announces the conclusion of a Letter of Intent for an Overseas Exclusive License Agreement for SI-6603, a Novel Treatment for Lumbar Disc Herniation

06.15.2016 Seikagaku announces Acquisition of Treasury Stocks （17KB）

読む Seikagaku announces Acquisition of Treasury Stocks

05.12.2016 Consolidated Financial Results for Fiscal 2015 (Year Ended March 31, 2016)

読む Consolidated Financial Results for Fiscal 2015 (Year Ended March 31, 2016)

05.12.2016 Seikagaku Announces a New Mid-term Management Plan (Fiscal 2016 to Fiscal 2018) （54KB）

読む Seikagaku Announces a New Mid-term Management Plan (Fiscal 2016 to Fiscal 2018)

03.10.2016 Seikagaku Announces a Change in Sales Partner for MucoUp Surgical Aid for Endoscopic Mucosal Resection in Japan （37KB）

読む Seikagaku Announces a Change in Sales Partner for MucoUp Surgical Aid for Endoscopic Mucosal Resection in Japan

02.15.2016 Seikagaku Announces New Drug Application Approval for the Ophthalmic Surgical Aid SHELLGAN 0.5 Ophthalmic Viscoelastic Solution （94KB）

読む Seikagaku Announces New Drug Application Approval for the Ophthalmic Surgical Aid SHELLGAN 0.5 Ophthalmic Viscoelastic Solution

02.02.2016 Consolidated Financial Results for the Thrid Quarter of Fiscal 2015

読む Consolidated Financial Results for the Thrid Quarter of Fiscal 2015

02.02.2016 Seikagaku Announces Discontinuation of Development of SI-657,an Additional Indication for ARTZ （41KB）

読む Seikagaku Announces Discontinuation of Development of SI-657,an Additional Indication for ARTZ

12.25.2015 Seikagaku Announces U.S. FDA Approval for VISCO-3, a Joint Function Improving Agent Supplied as a Three-Injection Kit （41KB）

読む Seikagaku Announces U.S. FDA Approval for VISCO-3, a Joint Function Improving Agent Supplied as a Three-Injection Kit

11.06.2015 Consolidated Financial Results for the Second Quarter of Fiscal Year 2015

読む Consolidated Financial Results for the Second Quarter of Fiscal Year 2015

08.28.2015 Seikagaku Announces Termination of the License Agreement with Can-Fite BioPharma Ltd. for a Therapeutic Agent for Rheumatoid Arthritis （41KB）

読む Seikagaku Announces Termination of the License Agreement with Can-Fite BioPharma Ltd. for a Therapeutic Agent for Rheumatoid Arthritis

07.31.2015 Consolidated Financial Results for the First Quarter of Fiscal 2015

読む Consolidated Financial Results for the First Quarter of Fiscal 2015

05.12.2015 Consolidated Financial Results for Fiscal 2014 (Year Ended March 31, 2015)

読む Consolidated Financial Results for Fiscal 2014 (Year Ended March 31, 2015)

02.03.2015 Consolidated Financial Results for the Thrid Quarter of Fiscal 2014

読む Consolidated Financial Results for the Thrid Quarter of Fiscal 2014

01.09.2015 Seikagaku Announces the Start of Operation of ARTZ Dispo Production Facilities (No. 5 Production Building at the Takahagi Plant) （58KB）

読む Seikagaku Announces the Start of Operation of ARTZ Dispo Production Facilities (No. 5 Production Building at the Takahagi Plant)

11.07.2014 Consolidated Financial Results for the Second Quarter of Fiscal Year 2014

読む Consolidated Financial Results for the Second Quarter of Fiscal Year 2014

10.16.2014 Seikagaku Announces the Opening of the SEIKAGAKU U.S.A. Representative Office （41KB）

読む Seikagaku Announces the Opening of the SEIKAGAKU U.S.A. Representative Office

07.31.2014 Consolidated Financial Results for the First Quarter of Fiscal Year 2014

読む Consolidated Financial Results for the First Quarter of Fiscal Year 2014

06.05.2014 Seikagaku Announces Results of Phase III Clinical Trial in Japan for SI-6603, Indicated for Treatment of Lumbar Disc Herniation （69KB）

読む Seikagaku Announces Results of Phase III Clinical Trial in Japan for SI-6603, Indicated for Treatment of Lumbar Disc Herniation

05.13.2014 Consolidated Financial Results for Fiscal 2013 (Year Ended March 31, 2014)

読む Consolidated Financial Results for Fiscal 2013 (Year Ended March 31, 2014)

05.07.2014 Seikagaku Initiates a Phase II/III Clinical Trial for SI-614, Indicated for Treatment of Dry Eye, in the U.S. （13KB）

読む Seikagaku Initiates a Phase II/III Clinical Trial for SI-614, Indicated for Treatment of Dry Eye, in the U.S.

02.04.2014 Consolidated Financial Results for the Thrid Quarter of Fiscal 2013

読む Consolidated Financial Results for the Thrid Quarter of Fiscal 2013

01.30.2014 Seikagaku Submits New Drug Application for SI-6603 in Japan for Treatment of Lumbar Disc Herniation （24KB）

読む Seikagaku Submits New Drug Application for SI-6603 in Japan for Treatment of Lumbar Disc Herniation

01.14.2014 Seikagaku Announces Confirmation of Victory in the Gel-One Patent Infringement Lawsuit （41KB）

読む Seikagaku Announces Confirmation of Victory in the Gel-One Patent Infringement Lawsuit

11.06.2013 Consolidated Financial Results for the Second Quarter of Fiscal Year 2013

読む Consolidated Financial Results for the Second Quarter of Fiscal Year 2013

08.07.2013 Seikagaku Announces Top-Line Results from a Phase III Clinical Trial for SI-6603, Indicated for Treatment of Lumbar Disc Herniation, in Japan （51KB）

読む Seikagaku Announces Top-Line Results from a Phase III Clinical Trial for SI-6603, Indicated for Treatment of Lumbar Disc Herniation, in Japan

07.30.2013 Consolidated Financial Results for the First Quarter of Fiscal Year 2013

読む Consolidated Financial Results for the First Quarter of Fiscal Year 2013

07.30.2013 Revision of Dividend Forecast for Year Ending March 31, 2014 and Abolition of the Shareholder Special Benefit Plan （16KB）

読む Revision of Dividend Forecast for Year Ending March 31, 2014 and Abolition of the Shareholder Special Benefit Plan

05.10.2013 Consolidated Financial Results for Fiscal 2012 (Year Ended March 31, 2013)

読む Consolidated Financial Results for Fiscal 2012 (Year Ended March 31, 2013)

04.23.2013 Seikagaku Initiates a Phase III Clinical Trial for SI-6603, Indicated for Treatment of Lumbar Disc Herniation, in the U.S. （11KB）

読む Seikagaku Initiates a Phase III Clinical Trial for SI-6603, Indicated for Treatment of Lumbar Disc Herniation, in the U.S.

02.07.2013 Seikagaku Initiates a Phase II Clinical Trial for SI-613, Indicated for Treatment of Knee Osteoarthritis （81KB）

読む Seikagaku Initiates a Phase II Clinical Trial for SI-613, Indicated for Treatment of Knee Osteoarthritis

02.02.2013 Consolidated Financial Results for the Thrid Quarter of Fiscal 2012

読む Consolidated Financial Results for the Thrid Quarter of Fiscal 2012

01.15.2013 Seikagaku Announces Changes in the Organization and Personnel （30KB）

読む Seikagaku Announces Changes in the Organization and Personnel

12.25.2012 Seikagaku and Kaken Conclude an Exclusive Distributorship Agreement for SI-6603, Indicated for Treatment of Lumbar Disc Herniation, in Japan （34KB）

読む Seikagaku and Kaken Conclude an Exclusive Distributorship Agreement for SI-6603, Indicated for Treatment of Lumbar Disc Herniation, in Japan

11.06.2012 Consolidated Financial Results for the Second Quarter of Fiscal Year 2012

読む Consolidated Financial Results for the Second Quarter of Fiscal Year 2012

10.01.2012 Seikagaku Announces the Completion of New Production Facilities for Gel-One （71KB）

読む Seikagaku Announces the Completion of New Production Facilities for Gel-One

09.26.2012 Seikagaku announces the revision of financial forecast for the first six-month of fiscal 2012 ending March 2013 （40KB）

読む Seikagaku announces the revision of financial forecast for the first six-month of fiscal 2012 ending March 2013

08.10.2012 The U.S. Court Ruled on Gel-One Patent Infringement Case （8KB）

読む The U.S. Court Ruled on Gel-One Patent Infringement Case

07.31.2012 Consolidated Financial Results for the First Quarter of Fiscal Year 2012

読む Consolidated Financial Results for the First Quarter of Fiscal Year 2012

05.10.2012 Consolidated Financial Results for Fiscal 2011 (Year Ended March 31, 2012)

読む Consolidated Financial Results for Fiscal 2011 (Year Ended March 31, 2012)

05.10.2012 Seikagaku Announces a New Mid-term Management Plan （78KB）

読む Seikagaku Announces a New Mid-term Management Plan

05.10.2012 Seikagaku and Kaken Conclude a Basic Distributorship Agreement for SI-6603, Indicated for Treatment of Lumbar Disc Herniation （8KB）

読む Seikagaku and Kaken Conclude a Basic Distributorship Agreement for SI-6603, Indicated for Treatment of Lumbar Disc Herniation

04.24.2012 Seikagaku and Biotie Agree to Terminate the Anti-VAP-1 Monoclonal Antibody License Agreement （29KB）

読む Seikagaku and Biotie Agree to Terminate the Anti-VAP-1 Monoclonal Antibody License Agreement

02.03.2012 Consolidated Financial Results for the Thrid Quarter of Fiscal 2011

読む Consolidated Financial Results for the Thrid Quarter of Fiscal 2011

01.23.2012 Seikagaku Initiates a Phase II Clinical Trial in the United States for SI-614, Indicated for Treatment of Dry Eye （32KB）

読む Seikagaku Initiates a Phase II Clinical Trial in the United States for SI-614, Indicated for Treatment of Dry Eye

01.05.2012 Seikagaku Announces a Change in Sales Partner for SUPARTZ in the U.S. （46KB）

読む Seikagaku Announces a Change in Sales Partner for SUPARTZ in the U.S.

12.20.2011 Announcement of the Absorption-type Merger (Simple merger, Short-form merger) of a Consolidated Subsidiary （34KB）

読む Announcement of the Absorption-type Merger (Simple merger, Short-form merger) of a Consolidated Subsidiary

11.10.2011 Seikagaku announces the start of a Phase III clinical trial in Japan for SI-6603, indicated for treatment of lumbar disc herniation （27KB）

読む Seikagaku announces the start of a Phase III clinical trial in Japan for SI-6603, indicated for treatment of lumbar disc herniation

11.08.2011 Consolidated Financial Results for the Second Quarter of Fiscal 2011

読む Consolidated Financial Results for the Second Quarter of Fiscal 2011

10.11.2011 Announcement of the Transfer of Emdogain Gel, a Medical Device Used in Dentistry （10KB）

読む Announcement of the Transfer of Emdogain Gel, a Medical Device Used in Dentistry

09.28.2011 Seikagaku announces the revision of financial forecast for the first six-month of fiscal 2011 ending March 2012 （38KB）

読む Seikagaku announces the revision of financial forecast for the first six-month of fiscal 2011 ending March 2012

08.10.2011 Seikagaku announces an additional clinical trial in Japan for SI-6603, indicated for treatment of lumbar disc herniation （33KB）

読む Seikagaku announces an additional clinical trial in Japan for SI-6603, indicated for treatment of lumbar disc herniation

07.29.2011 Consolidated Financial Results for the First Quarter of Fiscal Year 2011

読む Consolidated Financial Results for the First Quarter of Fiscal Year 2011

05.11.2011 Consolidated Financial Results for Fiscal 2010 (Year Ended March 31, 2011)

読む Consolidated Financial Results for Fiscal 2010 (Year Ended March 31, 2011)

05.11.2011 Notice of Expansion of ARTZ Dispo® Production Facilities (Construction of the No. 5 Production Building at the Takahagi Plant) （88KB）

読む Notice of Expansion of ARTZ Dispo® Production Facilities (Construction of the No. 5 Production Building at the Takahagi Plant)

05.11.2011 Notice Regarding the Impact of the Great East Japan Earthquake(Third Report) （87KB）

読む Notice Regarding the Impact of the Great East Japan Earthquake(Third Report)

05.11.2011 Notice Regarding Lawsuits to Seikagaku （11KB）

読む Notice Regarding Lawsuits to Seikagaku

04.11.2011 Notice Regarding the Impact of the Great East Japan Earthquake(Second Report) （87KB）

読む Notice Regarding the Impact of the Great East Japan Earthquake(Second Report)

03.30.2011 Seikagaku Announces Withdrawal of PMA for Additional Indication of SUPARTZ® in the U.S. （102KB）

読む Seikagaku Announces Withdrawal of PMA for Additional Indication of SUPARTZ® in the U.S.

03.29.2011 Seikagaku Announces the Discontinuation of Research Reagent Business at Its Subsidiary （12KB）

読む Seikagaku Announces the Discontinuation of Research Reagent Business at Its Subsidiary

03.24.2011 Seikagaku announces U.S. FDA approval of Gel-One, a single injection Hyaluronic Acid injectable treatment for osteoarthritis pain of the knee. （28KB）

読む Seikagaku announces U.S. FDA approval of Gel-One, a single injection Hyaluronic Acid injectable treatment for osteoarthritis pain of the knee.

03.16.2011 Notice regarding the impact of the Tohoku Pacific Offshore Earthquake （8KB）

読む Notice regarding the impact of the Tohoku Pacific Offshore Earthquake

02.01.2011 Consolidated Financial Results for the Third Quarter of Fiscal 2010

読む Consolidated Financial Results for the Third Quarter of Fiscal 2010

12.14.2010 Seikagaku announces on top-line results from phase II/III clinical trial in Japan of SI-6603, indicated for treatment on lumbar disc herniation （12KB）

読む Seikagaku announces on top-line results from phase II/III clinical trial in Japan of SI-6603, indicated for treatment on lumbar disc herniation

11.09.2010 Consolidated Financial Results for the Second Quarter of Fiscal 2010

読む Consolidated Financial Results for the Second Quarter of Fiscal 2010

07.30.2010 Consolidated Financial Results for the First Quarter of Fiscal Year 2010

読む Consolidated Financial Results for the First Quarter of Fiscal Year 2010

06.25.2010 Seikagaku Corporation submits Amendment to Premarket Approval Application for Gel-200 to U.S. Food and Drug Administration （67KB）

読む Seikagaku Corporation submits Amendment to Premarket Approval Application for Gel-200 to U.S. Food and Drug Administration

05.11.2010 Consolidated Financial Results for Fiscal 2009 (Year Ended March 31, 2010)

読む Consolidated Financial Results for Fiscal 2009 (Year Ended March 31, 2010)

09.28.2009 The application of SUPARTZ® was submitted to FDA for additional indication of treatment of pain associated with shoulder osteoarthritis （12KB）

読む The application of SUPARTZ® was submitted to FDA for additional indication of treatment of pain associated with shoulder osteoarthritis

07.31.2009 Consolidated Financial Results for the First Three Months of Fiscal 2009

読む Consolidated Financial Results for the First Three Months of Fiscal 2009

05.29.2009 Conclusion of an Exclusive Distributorship Agreement for Gel-200 with Zimmer, Inc. of the U.S. （75KB）

読む Conclusion of an Exclusive Distributorship Agreement for Gel-200 with Zimmer, Inc. of the U.S.

05.12.2009 Consolidated Financial Results for Fiscal 2008 (Year Ended March 31, 2009)

読む Consolidated Financial Results for Fiscal 2008 (Year Ended March 31, 2009)

03.10.2009 Announcement of the Mid-term Management Plan （47KB）

読む Announcement of the Mid-term Management Plan

02.03.2009 Consolidated Financial Results for the First Nine Months of Fiscal 2008

読む Consolidated Financial Results for the First Nine Months of Fiscal 2008